Floatz logo

Prednisone

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

AstraZenecaSmall moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
89/ 100

Competitive context

202 Active assets in the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cohort.

Asset / SponsorPhaseRating
Etoposide
Weill Medical College of Cornell University
Phase 2BBB
Chlorambucil
Ascentage Pharma Group Inc.
Phase 4BBB
Lisaftoclax
Henan Cancer Hospital
Phase 3BBB
Irinotecan
IGM Biosciences, Inc.
Phase 2BBB
Rituximab
M.D. Anderson Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

Prednisone is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
74 / 100
View asset →
diffuse large B-cell lymphomaActive
BBB
Indicative · Phase 4
74 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedActive
BBB
Indicative · Phase 4
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →